Isoform-selective FGFR inhibition as pioneer in cancer therapy: heterocyclic scaffold optimization strategies, mechanistic insights, and future directions
- DOI
- 10.1080/17568919.2026.2748642
- Published
- 2026-10-27
- Container
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/17568919.2026.2748642,
title = {Isoform-selective FGFR inhibition as pioneer in cancer therapy: heterocyclic scaffold optimization strategies, mechanistic insights, and future directions},
author = {Agnidipta Das and Nehal Purohit and Amit Kumar and Vikas Jaitak},
year = {2026},
journal = {Future Medicinal Chemistry},
doi = {10.1080/17568919.2026.2748642},
url = {https://doi.org/10.1080/17568919.2026.2748642}
}RIS
TY - JOUR TI - Isoform-selective FGFR inhibition as pioneer in cancer therapy: heterocyclic scaffold optimization strategies, mechanistic insights, and future directions AU - Agnidipta Das AU - Nehal Purohit AU - Amit Kumar AU - Vikas Jaitak PY - 2026 JO - Future Medicinal Chemistry DO - 10.1080/17568919.2026.2748642 UR - https://doi.org/10.1080/17568919.2026.2748642 ER -
APA
Das, A., Purohit, N., Kumar, A., & Jaitak, V. (2026). Isoform-selective FGFR inhibition as pioneer in cancer therapy: heterocyclic scaffold optimization strategies, mechanistic insights, and future directions. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2026.2748642
Source records
- crossref · retrieved 2026-11-10T14:05:00.600Z